European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Recording: Developments in perioperative immunotherapy for bladder and kidney cancers

Presenters:

A. Necchi, Milan (IT)
A. Bex, London (GB)
J. Bedke, Tübingen (DE)

Published Thu, 24 Jun 2021
Recorded WebinarKidney CancerBladder CancerOncologyEAU Section Of Oncological Urology
OrganiserEuropean School of Urology (ESU)
CMENot approved
DurationApprox. 70 minutes

Latest developments and future directions of perioperative immunotherapy in bladder cancer

Old paradigms and next destinations of perioperative immune-checkpoint inhibition in kidney cancer

Clinical case-series: Perioperative treatment with immune-checkpoint inhibitors in bladder and renal cancer

Recent developments in the use of immune-checkpoint inhibitors for the treatment of urologic malignancies, primarily for bladder and kidney cancers, provided healthcare providers and physician scientists with a significant momentum resulting in a number of newer therapeutic indications and clinical trials in the field. As such, this wave of therapeutic development is currently addressed to the multidisciplinary treatment of localized disease, i.e. at clinical stages that conventionally define the disease as amenable to radical resection.

In addition to the noteworthy developments of immunotherapy strategies into the preoperative setting, most recent data from large clinical trials has revitalized the role of postoperative, adjuvant immunotherapy in bladder and kidney cancers, potentially setting new therapeutic indications in these tumours.

In brief, the aims of the webinar:

To provide all the physicians and healthcare providers involved in the treatment of urologic tumors with the state-of-the art on the use of immune-checkpoint inhibitors in bladder and kidney cancers.

To provide urologists with an overview of the ongoing clinical trials throughout the clinical stages, with a special focus on neoadjuvant and adjuvant stages.

To discuss the optimal clinical management of perioperative immunotherapy, the alternative therapeutic solutions, and the major challenges to the use of checkpoint inhibition in early-stage disease.

Contact our organiser

European School of Urology (ESU)

Email:  educationonline@uroweb.org

Share this event

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer